Equities
Health CareMedical Equipment and Services
  • Price (NOK)215.00
  • Today's Change-2.00 / -0.92%
  • Shares traded45.75k
  • 1 Year change+37.38%
  • Beta0.3087
Data delayed at least 15 minutes, as of Feb 11 2026.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Medistim ASA is a Norway-based company engaged in the provision of medical equipment and technology. It develops, manufactures and distributes medical devices that measure blood flow and visualize atherosclerosis, and thereby help improve the outcome of cardiac and vascular surgery. The Company provides Transit Time Flow Measurement (TTFM) and ultrasound imaging to the global market to enable medical professionals to reduce risk and enhance quality of cardiac, vascular and transplant surgery. Medistim’s activities are divided into two business units: Own Products Category and Third-Party Products Category. Furthermore, the Company has several subsidiaries, including Medistim USA Inc, Medistim Norge AS and Medistim Japan KK.

  • Revenue in NOK (TTM)668.61m
  • Net income in NOK142.42m
  • Incorporated1995
  • Employees154.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Guerbet SA9.17bn87.65m2.03bn2.91k34.840.47442.550.22110.40640.406464.2529.850.78650.5464.90278,715.700.46190.920.60551.2078.0376.510.58731.191.031.460.517264.797.050.5853-32.61-15.50-0.8569--
Affluent Medical SAS46.64m-166.99m2.41bn76.00--6.69--51.65-0.3759-0.37590.10510.53650.0709--0.954159,681.16-25.40-23.76-32.61-27.591.34-226.93-358.01-1,815.40---924.300.5030------5.84------
Prim SA2.72bn164.83m2.55bn954.0014.381.698.820.93520.91760.917614.137.801.171.974.17251,008.807.096.2710.408.5038.7737.706.055.851.20144.870.139963.107.689.08-13.83-0.536613.506.35
Median Technologies SA264.01m-249.07m2.56bn211.00------9.70-1.16-1.161.23-2.080.8894-12.983.9296,717.84-83.91-60.70---232.35102.73102.32-94.35-97.730.3543-26.56----3.2520.72-9.83--43.77--
Tristel Plc603.59m86.26m2.67bn265.0031.096.2221.804.430.13830.13830.96760.69151.041.935.81175,328.3014.859.6017.5711.0980.6280.9014.2911.042.96--0.1512120.7110.807.962.335.42-3.5918.10
Onward Medical NV12.60m-437.79m2.72bn102.00--6.91--216.08-0.866-0.8660.02490.62090.0215--9.1110,901.96-74.86-55.03-92.84-61.1977.16---3,475.81-39,652.374.30-17.130.352--236.76--1.26--3.88--
Stratec SE2.91bn177.30m2.82bn1.42k15.921.047.230.97011.291.2921.1319.750.58251.325.65177,177.203.556.724.247.9629.0928.416.099.631.656.850.355237.35-4.733.764.242.35-7.49-6.51
Medistim ASA668.61m142.42m3.98bn154.0027.869.4723.555.957.797.7936.5622.911.250.76799.674,341,637.0026.7221.9833.0927.1981.2178.6621.3020.322.03--0.048485.046.889.120.00878.1112.5316.89
CellaVision AB813.18m164.01m4.11bn236.0025.094.3319.965.066.426.4231.8237.210.72012.026.80--14.5214.7116.2216.9668.5068.3820.1719.852.9725.880.028141.974.949.998.7811.3420.7629.67
COLTENE Holding AG2.98bn177.45m4.13bn1.18k23.303.6915.831.392.402.4040.2215.131.311.346.40204,684.507.8010.5914.2618.4366.1162.195.957.640.70437.620.360685.663.06-1.7971.310.4306-15.4510.76
IVF Hartmann Holding AG1.98bn235.78m4.30bn309.0018.252.3914.332.187.927.9266.3960.570.89643.287.88526,221.1010.697.9012.919.6855.7154.0611.939.133.79--0.004248.547.332.8534.0210.78-28.9419.92
Ion Beam Applications SA6.76bn192.59m5.24bn2.10k26.913.7715.700.77560.56770.567720.174.060.97562.733.28281,693.602.781.5012.034.6431.2134.392.852.150.62097.410.363170.816.7512.01201.573.997.6925.86
Revenio Group Oyj1.23bn209.51m5.92bn248.0028.284.7822.954.800.69310.69314.084.100.80872.916.94452,352.7013.6514.1115.7517.5371.8670.9616.8820.611.8010.720.103653.127.1915.91-3.2014.6422.935.92
Data as of Feb 11 2026. Currency figures normalised to Medistim ASA's reporting currency: Norwegian Krone NOK

Institutional shareholders

51.65%Per cent of shares held by top holders
HolderShares% Held
Aeternum Management ASas of 13 Jan 20261.82m9.90%
SEB Investment Management AB (Denmark)as of 31 Dec 20251.44m7.84%
ODIN Forvaltning ASas of 28 Nov 20251.09m5.97%
Swedbank Robur Fonder ABas of 30 Dec 2025970.00k5.29%
Universal-Investment-Gesellschaft mbH (Invt Mgmt)as of 25 Nov 2024902.48k4.92%
Holberg Fondsforvaltning ASas of 13 Jan 2026765.00k4.17%
Joh. Berenberg, Gossler & Co. KG (Investment Management)as of 31 Jan 2025734.89k4.01%
ODIN Forvaltning AS (Sweden)as of 13 Jan 2026600.00k3.27%
Fidelity Management & Research Co. LLCas of 31 Dec 2025588.34k3.21%
Handelsbanken Fonder ABas of 31 Jan 2026562.38k3.07%
More ▼
Data from 30 Sep 2025 - 31 Jan 2026Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.